Skip to main content

Tweets

Swiss RA registry assessed outcomes after 1st JAKi. 400 RA pts starting/failing JAKi were switched to 2nd JAKi or TNFi or other MOA biologic. ~40% had prior bDMARDs. Retention was higher w/ 2nd JAK (918d)i vs other options. TNFi (335d) or OMA (918d). https://t.co/3A3KwVcTCN https://t.co/UFLPGfmzNv
Dr. John Cush @RheumNow ( View Tweet )
3 years 5 months ago
Herpes Zoster with JAK Inhibitors A recent review a higher HZ risk with JAKi therapy shows the HZ-risk in RA and UC to be higher than PsA when treated with usual doses of TOFA, especially those given higher TOFA doses or concomitant glucocorticoids. https://t.co/BO7CgcuRKR https://t.co/gyMivn5YxL
Dr. John Cush @RheumNow ( View Tweet )
3 years 5 months ago
Is JAKi therapy safe in RA-ILD pts? Italian retrospective study (2018-June 2022) w/ 43 RA pts & HRCT proven ILD (med age 69yrs) & Rx w/ JAKi. After 19 mos F/U, the FVC was stable in 79%, improved in 11%, & worse in 11%. DLCO & HRCT trend was similar. https://t.co/bAqa5wKIYE https://t.co/LnlcQtQnm8
Dr. John Cush @RheumNow ( View Tweet )
3 years 5 months ago
The EMAs CHMP has recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of moderate to severe plaque psoriasis in adults. https://t.co/WztKcNDFl1 https://t.co/Cq3Cyr3YqX
Dr. John Cush @RheumNow ( View Tweet )
3 years 5 months ago
Rretroperitoneal fibrosis Tx is fraut-steroids, tamoxifen, MMF, B cell therapy? OL trial in 8 RPF pts used steroids & mTOR inhibitor sirolimus (2mg/d x 3d; 1mg/d); 12 & 48wks - decr in fibrous tissue 50%, ESR 70%, IgG4 50% w/ normalized renal funct. https://t.co/9BJchCctDi

Dr. John Cush @RheumNow ( View Tweet )

3 years 5 months ago
RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts - study shows that NFATC1 associated superenhancer RNA, which is formed during osteoblast differentiation, can be used as a treatment target to reduce erosions https://t.co/gCITdJKPRP https://t.co/HENbYJcOId
Dr. John Cush @RheumNow ( View Tweet )
3 years 5 months ago
Studies in 76 systemic sclerosis (SSc) pts (& animal models of SSc) show fibroblast A20 (enzyme) is downregulated and promotes fibrosis in SSc; but is repressed by DREAM, an A20 negative transcriptional regulator. https://t.co/30PuO4XRuq https://t.co/VJuAJHGbut
Dr. John Cush @RheumNow ( View Tweet )
3 years 5 months ago
Join us at RheumNow Live this March! Dr. Janet Pope ( @janetbirdnope) will be back to discuss decisive therapeutics in RA. https://t.co/0IkJsGpH6s https://t.co/TwM6AAW97X
Dr. John Cush @RheumNow ( View Tweet )
3 years 5 months ago
US population mortality rates compared dermatomyositis (DM) vs polymyositis (PM) in 1981 (12,249) & 2020 (23,608). Downward trend in DM/PM mortality (<7%); plus PM/DM was 2X more likely to be one of mult causes, instead of, sole cause of death. https://t.co/9KZKr8JxUE https://t.co/7acK0eHVku
Dr. John Cush @RheumNow ( View Tweet )
3 years 5 months ago
Systematic review of MRI confirm degenerative meniscus tears compared arthroscopic meniscectomy (APM) vs non-surgical or sham Rx. Results: 10 trials, 605 patients showed at 24 mos F/U, no advantage in Function or QOL favoring APM - rec conservative Rx https://t.co/4CwicQ9Jac https://t.co/3IrSRkNgqp
Dr. John Cush @RheumNow ( View Tweet )
3 years 5 months ago
How do you treat latent TB? This and more on last week's RheumNow podcast. https://t.co/4gUXFUDTFM https://t.co/TgT6ZyewZJ
Dr. John Cush @RheumNow ( View Tweet )
3 years 5 months ago
Can something as simple as a cup of coffee with milk have an anti-inflammatory effect in humans? Apparently so, according to a new study. A combination of proteins and antioxidants doubles the anti-inflammatory properties. https://t.co/As8lhxnifp https://t.co/eZKD8Y6oTx
Dr. John Cush @RheumNow ( View Tweet )
3 years 5 months ago
×